Details for Patent: 5,855,912
✉ Email this page to a colleague
Title: | Pharmaceutical compositions for piperidinalkanol compounds |
Abstract: | The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient. |
Inventor(s): | Ortyl; Thomas T. (Overland Park, KS), Skultety; Paul F. (Leawood, KS), Mitchell; Kristen C. (Lee's Summit, MO), Phadke; Deepak S. (Olathe, KS), Attarchi; Faraneh (Kansas City, MO), Pierce; Marguerite L. (Fairway, KS), Schoeneman; Aaron W. (Lee's Summit, MO), Schnitz; Joseph M. (Kansas City, MO) |
Assignee: | Hoechst Marion Roussel, Inc. (Cincinnati, OH) |
Filing Date: | Oct 03, 1997 |
Application Number: | 08/943,460 |
Claims: | 1. A pharmaceutical composition in solid unit dosage form prepared by a process comprising, blending together a compound of the formula; ##STR10## wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof, with microcrystalline cellulose, lactose and pregelatinized starch; adding a solution of gelatin in water with mixing; drying and milling the mixture; and adding croscarmellose sodium with mixing. 2. A pharmaceutical composition in solid unit dosage form according to claim 1 wherein the microcrystalline cellulose, lactose, pregelatinized starch, gelatin and croscarmellose sodium are combined in amounts of about 33.8%, 33.8%, 9.6%, 3.5% and 4.8%, respectively, by weight of the composition. 3. A pharmaceutical composition in solid unit dosage form according to claim 1 wherein the microcrystalline cellulose, lactose, pregelatinized starch, gelatin, and croscarmellose sodium are combined in amounts of about 33.7%, 33.7%, 9.6%, 3.5%, and 4.8%, respectively, by weight of the composition. 4. A pharmaceutical composition in solid unit dosage form prepared by a process comprising blending together a compound of the formula; ##STR11## wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof, with microcrystalline cellulose, lactose and pregelatinized starch; adding a solution of gelatin in water with mixing; drying and milling the granulated mixture; adding croscarmellose sodium with mixing; and adding magnesium stearate with mixing. 5. A pharmaceutical composition in solid unit dosage form according to claim 4 wherein the final mixture is pressed into tablets. 6. A pharmaceutical composition in solid unit dosage form according to claim 4 wherein the microcrystalline cellulose, lactose, pregelatinized starch, gelatin, croscarmellose sodium and magnesium stearate are combined in amounts of about 33.7%, 33.7%, 9.6%, 3.5%, 4.8% and 0.5%, respectively, by weight of the composition. 7. A pharmaceutical composition in solid unit dosage form, comprising; a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof wherein said piperidinoalkanol compound is of the formula: ##STR12## wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof; and b) croscarmellose sodium, microcrystalline cellulose, lactose, pregelatinized starch and gelatin in amounts of about 1% to about 10%, 20% to about 85%, 20% to about 85%, 1% to about 30% and 1% to about 15%, respectively, by weight of the composition. 8. The pharmaceutical composition in solid unit dosage form according to claim 7 wherein croscarmellose sodium, microcrystalline cellulose, lactose, pregelatinized starch and gelatin are present in amounts of about 4.8%, 33.8%, 33.8%, 9.6% and 3.5%, respectively, by weight of the composition. 9. A pharmaceutical composition in solid unit dosage form, comprising; a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof wherein said piperidinoalkanol compound is of the formula: ##STR13## wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof; and b) croscarmellose sodium, microcrystalline cellulose, lactose, pregelatinized starch, gelatin and magnesium stearate in amounts of about 1% to about 10%, 20% to about 85%, 20% to about 85%, 1% to about 30%, 1% to about 15% and 0.05% to about 3.0%, respectively, by weight of the composition. 10. The pharmaceutical composition in solid unit dosage form according to claim 9 wherein croscarmellose sodium, microcrystalline cellulose, lactose, pregelatinized starch, gelatin and magnesium stearate are present in amounts of about 4.8%, 33.7%, 33.7%, 9.6%, 3.5% and 0.5%, respectively, by weight of the composition. 11. The pharmaceutical composition in solid unit dosage form according to claim 9 wherein croscarmellose sodium, microcrystalline cellulose, lactose, pregelatinized starch, gelatin and magnesium stearate are present in amounts of about 4.8%, 25.7%, 25.7%, 9.6%, 3.5% and 0.75%, respectively, by weight of the composition. 12. A pharmaceutical composition in solid unit dosage form, comprising; a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof wherein said piperidinoalkanol compound is of the formula: ##STR14## wherein X is a number ranging from about zero to 5, and the individual optical isomers thereof; and b) croscarmellose sodium, microcrystalline cellulose, pregelatinized starch, and magnesium stearate in amounts of about 1% to about 10%, 20% to about 85%, 5% to about 50% and 0.05% to about 3%, respectively, by weight of the composition. 13. The pharmaceutical composition in solid unit dosage form according to claim 12 wherein croscarmellose sodium, microcrystalline cellulose, pregelatinized starch, and magnesium stearate are present in amounts of about 6%, 33.3%, 30% and 0.75%, respectively, by weight of the composition. 14. The pharmaceutical composition in solid unit dosage form according to claim 4 wherein the microcrystalline cellulose, lactose, pregelatinized starch, gelatin, croscarmellose sodium and magnesium stearate are combined in amounts of about 33.8%, 33.8%, 9.6%, 3.5%, 4.8% and 0.5%, respectively, by weight of the composition. 15. The pharmaceutical composition according to claim 1 wherein X is zero. 16. The pharmaceutical composition according to claim 2 wherein X is zero. 17. The pharmaceutical composition according to claim 4 wherein X is zero. 18. The pharmaceutical composition according to claim 14 wherein X is zero. 19. The pharmaceutical composition according to claim 7 wherein X is zero. 20. The pharmaceutical composition according to claim 8 wherein X is zero. 21. The pharmaceutical composition according to claim 9 wherein X is zero. 22. The pharmaceutical composition according to claim 10 wherein X is zero. 23. The pharmaceutical composition according to claim 11 wherein X is zero. 24. The pharmaceutical composition according to claim 12 wherein X is zero. 25. The pharmaceutical composition according to claim 13 wherein X is zero. |